PWM
ALNY icon

PRW Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

PRW Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-35
Closed -$4K – 89
2019
Q1 		$4K Hold
35
– – ﹤0.01% 401
2018
Q4 		$3K Buy
+35
New +$2.69K ﹤0.01% 444

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PRW Wealth Management's ALNY Position: Q2 2019 in Review

PRW Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2019, closing a stake of 35 shares — an estimated $4K sold.

PRW Wealth Management first reported a position in ALNY in Q4 2018 and held it in 2 quarters. The position peaked at $4K in Q1 2019. 290 funds tracked by Wall St. Rank hold ALNY as of Q2 2019.

  • PRW Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • PRW Wealth Management sold 35 Alnylam Pharmaceuticals shares in Q2 2019, an estimated $4K.
  • PRW Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • PRW Wealth Management's Alnylam Pharmaceuticals position peaked at $4K in Q1 2019.
  • 290 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2019.

Based on PRW Wealth Management's 13F filing for Q2 2019, filed 12 Aug 2019.